News Eli Lilly makes $7.8bn takeover play for Centessa Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.
News Lilly strikes again, buying Calytrix in $1.5bn deal Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.